Deutsche Bank Pinpoints Uncertainties Nipping at Valeant’s Potential for Growth


Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled to see the biotech giant take a stride forward after quite a volatile year, better risk/reward is not enough to sway Deutsche Bank analyst Gregg Gilbert from the sidelines. What has left Gilbert cautiously optimistic on the company’s recovery, but dialing down his price target?

Story Continues